IFNγ directly counteracts imatinib-induced apoptosis of primary human CD34+ CML stem/progenitor cells potentially through the upregulation of multiple key survival factors-Reference-Cited by-同舟云学术

IFNγ directly counteracts imatinib-induced apoptosis of primary human CD34+ CML stem/progenitor cells potentially through the upregulation of multiple key survival factors

Published:2022-08-12 Issue:1 Volume:11 Page:
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Ujvari Dorina¹²,Malyukova Alena³,Zovko Ana⁴⁵,Yektaei-Karin Elham⁴⁵,Madapura Harsha S⁶,Keszei Marton⁶,Nagy Noemi³,Lotfi Kourosh⁷⁸,Björn Niclas⁹,Wallvik Jonas¹⁰,Stenke Leif⁴⁵,Salamon Daniel¹

Affiliation:

1. Department of Women’s and Children’s Health, Karolinska Institutet, Stockholm, Sweden

2. National Pandemic Center, Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden

3. Department of Cell and Molecular Biology, Karolinska Institute, Stockholm, Sweden

4. Division of Hematology, Karolinska University Hospital Solna, Stockholm, Sweden

5. Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden

6. Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, Stockholm, Sweden

7. Department of Hematology, Linköping University Hospital, Linköping, Sweden

8. Department of Medical and Health Sciences, Linköping University, Linköping, Sweden

9. Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden

10. Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2022.2109861

Reference29 articles.

1. Pushing the limits of targeted therapy in chronic myeloid leukaemia

2. Response and Resistance to BCR-ABL1-Targeted Therapies

3. Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia

4. Treatment and outcome of 2904 CML patients from the EUTOS population-based registry

5. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Imatinib inhibits oral squamous cell carcinoma by suppressing the PI3K/AKT/mTOR signaling pathway;Journal of Cancer;2024